Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

Clinical trial NCT06904196 · RECRUITING

Trial details

NCT number: NCT06904196
Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma Non-resectable

Start date: 2025-04-01
Primary completion: 2028-03-31
Enrollment: 78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.